Monlunabant for Diabetic Kidney Disease: Why a Negative CB1 Trial Matters
A phase 2 randomized trial of monlunabant, a second-generation CB1 inverse agonist, did not establish proof of concept in diabetic kidney disease. The result is important because negative trials help separate cannabinoid-pathway promise from clinical…
Cannabis Edibles, Alcohol, and Driving: What the JAMA Trial Shows
A JAMA Network Open crossover trial found that cannabis edibles combined with alcohol worsened simulated driving and subjective intoxication more than either substance alone. The study also shows why common field-sobriety signals can miss meaningful…
High-Dose CBD Significantly Reduced Neuropathic Pain in Spinal Cord Injury: What a New RCT Reveals
A new randomized controlled trial shows high-dose CBD neuropathic pain spinal cord injury treatment significantly reduces chronic neuropathic pain intensity. This placebo-controlled study found that oral CBD up to 800 mg/day led to meaningful pain relief…
CED Cannabis Science Digest: Withdrawal, Sleep, and Pediatric Signals
This digest highlights cannabis withdrawal symptom management alongside pediatric exposure and adolescent sleep risk signals. It provides evidence-aware insights for clinicians and caregivers. These public-health signals inform safer counseling and…
CED Cannabis Science Digest: 3 Toxicology and Safety Signals Worth Watching
This digest highlights the synthetic cannabinoid toxicity review and three verified cannabis safety signals. It covers acute cardiovascular presentations and immune-cell laboratory findings. These insights refine counseling on cannabis toxicology and…
CED Cannabis Science Digest: 3 Surgery, Pregnancy, and Pain Signals Worth Watching
Three additional cannabis science signals on surgery outcomes, prenatal safety messaging, and early pain-delivery research, preserved with clear evidence limits.
Cannabis Science Full Report: What a Phase 2 CBD Autism Trial Found
A 2026 phase 2 open-label cannabidiol autism trial reported early symptom improvement signals with mostly mild adverse events. The study was small and uncontrolled, limiting efficacy conclusions. This trial offers preliminary clinical insights into…
CED Cannabis Science Digest: 3 Evidence and Measurement Signals Worth Watching
This digest highlights 3 evidence and measurement signals in cannabis science that help separate clinical proof from preliminary data. It covers systematic reviews, a human HIV biomarker study, and improved cannabinoid measurement methods. These signals…
CED Cannabis Science Digest: 3 Additional Clinical Signals Worth Watching
This digest highlights 3 additional cannabis science signals that sharpen clinical counseling and research endpoints. These signals include Parkinson's nonmotor symptoms, cannabis use disorder endpoints, and cannabinoid hyperemesis syndrome…
Cannabis Use in Early-Onset Psychosis: What the New Meta-Analysis Shows
A 2026 meta-analysis found cannabis use and cannabis use disorder are common in early-onset psychosis and linked to a more complicated clinical picture, but it does not prove causation.
